VivoSeq
Oncology

Gastroesophageal Junction Adenocarcinoma

108

Pipeline Programs↗

68

Active Trials↗

51

Companies Involved↗

Gastroesophageal Junction Adenocarcinoma is a highly competitive landscape with 108 programs across 51 companies. The most active players are Gilead, Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd., Shanghai Henlius Biotech. 2 therapies are approved with 27 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

74/100

Pipeline Velocity

50/100

Mech. Concentration

13/100

Completion Rate

76/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Gilead logo

Gilead

1 program

Phase 1S

Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.

1 program

Phase 1Shanghai Henlius Biotech logo

Shanghai Henlius Biotech

2 programs

Phase 2CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

2 programs

Phase 2S

Sichuan Baili Pharmaceutical Co., Ltd.

2 programs

Phase 2S

Shanghai Runshi Pharmaceutical Technology Co., Ltd

2 programs

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

78%

Small molecule

112 of 144 classified programs — the dominant modality here.

22%ALL OTHERSMonoclonal antibody3021%Antibody–drug conjugate21%

Small molecule leads; the ring shows all 144 classified programs, each share of the total. Modality classified for 99% of 151 pipeline programs.

Analysis

Trial Status

108

clinical trials

Recruiting39 · 36%
Not yet recruiting24 · 22%
Completed19 · 18%
Unknown status14 · 13%
Active, not recruiting4 · 4%
Terminated4 · 4%
Other4 · 4%

Clinical Trials

Trial Activity

108 trials

Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Recruiting·Shanghai Henlius Biotech logoShanghai Henlius Biotech·Phase 2·NCT07115485·60 enrolled
Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
Recruiting·SSun Yat-sen University·Phase 3·NCT05918094·540 enrolled
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Recruiting·AstraZeneca logoAstraZeneca·Phase 2·NCT05702229·163 enrolled
Immune Checkpoint Inhibitor PD-1 Antibody Combined With Chemotherapy in the Perioperative Treatment of Locally Advanced Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT04908566·124 enrolled
XELOX Combined With Fruquintinib and Sintilimab Regimen Conversion Therapy for Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Only With Liver and/or Retroperitoneal Lymph Node Metastasis, a Prospective Single-arm, Multicenter Study
Recruiting·—·Phase 2·NCT06091423·43 enrolled
Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
Recruiting·BBeijing Biostar Pharmaceuticals Co., Ltd.·Phase 2/3·NCT06841679·778 enrolled
Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
Recruiting·AAkeso·Phase 2·NCT05960955·90 enrolled
A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma
Recruiting·FFudan University·Phase 2·NCT07492615·276 enrolled
Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Recruiting·FFujian Cancer Hospital·Phase 3·NCT06793917·269 enrolled
Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Recruiting·—·Phase 3·NCT06925243·682 enrolled
A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
Recruiting·Suzhou Suncadia Biopharmaceuticals Co., Ltd. logoSuzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 3·NCT07118527·600 enrolled
A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma
Recruiting·AAkeso·Phase 3·NCT06341335·506 enrolled
A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
Recruiting·RRemeGen Co., Ltd.·Phase 3·NCT07315750·555 enrolled
DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
Recruiting·RRemeGen Co., Ltd.·Phase 2/3·NCT06221748·90 enrolled
The Efficacy and Safety of LM-302 in Combination With Candonilimab and Capecitabine for First-Line Treatment in Patients With Unresectable Advanced, Recurrent, or Metastatic CLDN18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
Recruiting·SShanghai Zhongshan Hospital·Phase 2·NCT06587425·50 enrolled
Page 1 of 8

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)